Why the study?
Does NMDA inhibit thromboxane B2 synthesis and platelet aggregation in human platelets?
Does NMDA inhibit thromboxane B2 synthesis and platelet aggregation in human platelets?
NMDA demonstrates potent antiaggregating activity in human platelets by inhibiting thromboxane B2 synthesis and potentiating the effects of cyclo-oxygenase inhibitors.
Answers are grounded in this paper and cite their sources.
Animal data suggest novel antiplatelet pathway; leaves open confirmation in human platelets and clinical relevance.
In the present study the effect of N-methyl-D-aspartate (NMDA) on thromboxane B2 synthesis and on [Ca2+]i was studied in human platelets. 2. NMDA (10(-7) M) completely inhibited the synthesis of thromboxane B2 from exogenous arachidonic acid (AA), while it did not interfere with the aggregating effect of the thromboxane A2 receptor agonist U-46619. 3. NMDA (0.1 microM - 10 microM) dose-dependently increased intracellular calcium in washed platelets preloaded with fura 2 AM, and this effect was not additive with that of AA. 4. NMDA shifted the dose-response curve of AA to the right. At the highest AA concentrations platelet aggregation was not inhibited. 5. The antiaggregating effect of NMDA was not antagonized by N(G)-monomethyl-L-arginine (L-NMMA), a nitric oxide synthase (NOS) inhibitor. 6. Finally, NMDA (0.01 nM - 100 nM) associated with either aspirin or indomethacin significantly potentiated the antiaggregating activity of both cyclo-oxygenase inhibitors. 7. It was concluded that NMDA is a potent inhibitor of platelet aggregation and thromboxane B2 synthesis in human platelet rich plasma (PRP).
No takes yet. Share an insight, caveat, or question.
Franconi et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: